| Literature DB >> 29731986 |
I-Shiang Tzeng1,2,3, Chau Yee Ng4,5, Jau-Yuan Chen6,7, Li-Shya Chen8, Chin-Chieh Wu9.
Abstract
BACKGROUND: Recently, the multiphase method was proposed to estimate cohort effects after removing the effects of age and period in age-period contingency table data. Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and is strongly associated with cirrhosis, due to both alcohol and viral etiologies. In epidemiology, age-period-cohort (APC) model can be used to describe (or predict) the secular trend in HCC mortality.Entities:
Keywords: age-period-cohort; hepatocellular carcinoma; multiphase method; prediction
Year: 2018 PMID: 29731986 PMCID: PMC5929429 DOI: 10.18632/oncotarget.24868
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1HCC mortality rates per 100,000 by age and period, males, Taiwan, 1976–2010
Figure 2HCC mortality rates per 100,000 by age and period, females, Taiwan, 1976–2010
Estimated rate ratios and 95% conference intervals for effect of birth cohort on hepatocellular carcinoma mortality of males in Taiwan, 1891–1966
| Unweighted | Weighted | |||
|---|---|---|---|---|
| Effects | 95% CI for Effects | Effects | 95% CI for Effects | |
| Cohort | ||||
| (1891∼1966) | ||||
| 1891 | 0.75 | 0.62–0.89 | 0.71 | 0.59–0.84 |
| 1896 | 0.90 | 0.82–0.99 | 0.86 | 0.79–0.94 |
| 1901 | 0.91 | 0.85–0.97 | 0.81 | 0.73–0.90 |
| 1906 | 0.93 | 0.88–0.98 | 0.85 | 0.79–0.92 |
| 1911 | 0.97 | 0.92–1.02 | 0.89 | 0.84–0.94 |
| 1916 | 1.03 | 0.98–1.08 | 0.98 | 0.95–1.01 |
| 1921 | 1.01 | 0.97–1.06 | 0.98 | 0.96–1.00 |
| 1926 | 1.01 | 0.97–1.05 | 0.99 | 0.97–1.01 |
| 1931 | 1.06 | 1.01–1.10 | 1.03 | 1.01–1.05 |
| 1936 | 1.13 | 1.09–1.18 | 1.05 | 1.04–1.07 |
| 1941 | 1.09 | 1.04–1.14 | 1.04 | 1.03–1.06 |
| 1946 | 1.00 | REF | 1.00 | REF |
| 1951 | 0.87 | 0.82–0.92 | 0.93 | 0.91–0.95 |
| 1956 | 0.82 | 0.77–0.88 | 0.87 | 0.85–0.90 |
| 1961 | 0.77 | 0.70–0.85 | 0.74 | 0.70–0.78 |
| 1966 | 0.68 | 0.57–0.82 | 0.79 | 0.76–0.82 |
Note: REF = reference; CI = confidence interval.
Estimated rate ratios and 95% conference intervals for effect of birth cohort on hepatocellular carcinoma mortality of females in Taiwan, 1891–1966
| Unweighted | Weighted | |||
|---|---|---|---|---|
| Effects | 95% CI for Effects | Effects | 95% CI for Effects | |
| Cohort | ||||
| (1891∼1966) | ||||
| 1891 | 0.69 | 0.44–1.10 | 0.65 | 0.41–1.03 |
| 1896 | 0.84 | 0.66–1.07 | 0.78 | 0.61–1.00 |
| 1901 | 0.82 | 0.68–0.97 | 0.73 | 0.56–0.95 |
| 1906 | 0.85 | 0.74–0.97 | 0.78 | 0.68–0.89 |
| 1911 | 0.89 | 0.79–1.00 | 0.86 | 0.79–0.93 |
| 1916 | 1.01 | 0.90–1.12 | 0.98 | 0.94–1.02 |
| 1921 | 1.11 | 1.01–1.23 | 1.04 | 1.01–1.07 |
| 1926 | 1.17 | 1.06–1.30 | 1.03 | 1.01–1.05 |
| 1931 | 1.13 | 1.02–1.25 | 1.02 | 1.00–1.03 |
| 1936 | 1.16 | 1.05–1.28 | 1.02 | 1.00–1.03 |
| 1941 | 1 | REF | 1 | REF |
| 1946 | 0.86 | 0.77–0.97 | 0.97 | 0.95–0.99 |
| 1951 | 0.67 | 0.58–0.77 | 0.86 | 0.84–0.89 |
| 1956 | 0.74 | 0.62–0.88 | 0.79 | 0.75–0.83 |
| 1961 | 0.42 | 0.33–0.54 | 0.52 | 0.47–0.57 |
| 1966 | 0.49 | 0.31–0.78 | 0.49 | 0.44–0.54 |
Note: REF = reference; CI = confidence interval.
Estimated age and period effects of among males and females, Taiwan, 1976–2010
| Males | Females | |
|---|---|---|
| Effect | Effect | |
| Period | ||
| 1976–1980 | –0.25 | –0.32 |
| 1981–1985 | –0.10 | –0.15 |
| 1986–1990 | –0.08 | –0.16 |
| 1991–1995 | 0.04 | 0.02 |
| 1996–2000 | 0.11 | 0.20 |
| 2001–2005 | 0.16 | 0.25 |
| 2006–2010 | 0.13 | 0.16 |
| Age | ||
| 40–44 | –1.37 | –2.01 |
| 45–49 | –0.83 | –1.36 |
| 50–54 | –0.41 | –0.90 |
| 55–59 | –0.09 | –0.29 |
| 60–64 | 0.12 | 0.20 |
| 65–69 | 0.32 | 0.53 |
| 70–74 | 0.45 | 0.83 |
| 75–79 | 0.54 | 1.02 |
| 80–84 | 0.62 | 0.98 |
| 85+ | 0.67 | 1.00 |
| Constant | –6.74 | –7.89 |
Figure 3Plot of the unweighted and weighted effects with 95% confidence interval of males
Figure 4Plot of the unweighted and weighted effects with 95% confidence interval of females
Figure 5Age-adjusted mortality rate of death from hepatocellular carcinoma for men and women in Taiwan
Age-period contingency table of HCC mortality rate per 100,000 among males and females, Taiwan, 1976–2010
| Males | 1976–1980 | 1981–1985 | 1986–1990 | 1991–1995 | 1996–2000 | 2001–2005 | 2006–2010 |
|---|---|---|---|---|---|---|---|
| 40–44 | 31.41 | 33.10 | 33.20 | 31.24 | 30.40 | 29.10 | 23.26 |
| 45–49 | 46.50 | 55.13 | 52.88 | 53.61 | 49.79 | 47.66 | 42.25 |
| 50–54 | 68.11 | 72.47 | 74.56 | 81.73 | 81.65 | 74.19 | 69.12 |
| 55–59 | 84.12 | 97.32 | 98.96 | 115.57 | 127.55 | 117.70 | 100.19 |
| 60–64 | 103.58 | 120.45 | 115.71 | 143.74 | 164.14 | 168.20 | 145.35 |
| 65–69 | 126.15 | 140.12 | 138.76 | 160.29 | 186.58 | 204.31 | 203.50 |
| 70–74 | 135.44 | 147.79 | 170.44 | 195.56 | 201.40 | 223.00 | 253.46 |
| 75–79 | 145.41 | 178.22 | 186.70 | 226.86 | 243.87 | 234.63 | 263.24 |
| 80–84 | 123.63 | 160.33 | 175.09 | 229.23 | 267.55 | 264.61 | 276.39 |
| 85+ | 133.97 | 232.56 | 212.33 | 227.57 | 248.07 | 292.51 | 272.51 |
| Females | |||||||
| 40–44 | 6.75 | 6.14 | 4.90 | 5.11 | 3.46 | 2.88 | 3.03 |
| 45–49 | 11.99 | 11.10 | 9.21 | 9.76 | 6.49 | 5.76 | 4.90 |
| 50–54 | 18.20 | 16.23 | 14.78 | 15.53 | 14.15 | 11.78 | 10.20 |
| 55–59 | 27.57 | 30.06 | 24.45 | 28.43 | 28.65 | 28.04 | 23.68 |
| 60–64 | 35.23 | 39.48 | 41.09 | 44.75 | 55.75 | 52.97 | 48.01 |
| 65–69 | 43.49 | 54.68 | 52.09 | 66.36 | 76.92 | 89.05 | 82.80 |
| 70–74 | 50.40 | 61.49 | 65.48 | 87.47 | 111.46 | 130.60 | 131.32 |
| 75–79 | 66.47 | 72.02 | 77.57 | 105.09 | 127.37 | 153.26 | 160.98 |
| 80–84 | 60.12 | 74.79 | 81.83 | 101.26 | 139.41 | 175.41 | 184.90 |
| 85+ | 54.22 | 82.91 | 71.93 | 103.98 | 132.42 | 169.12 | 196.03 |